DelveInsight’s, “Knee osteoarthritis Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Knee osteoarthritis pipeline landscape. It covers the Knee osteoarthritis pipeline drug profiles, including Knee osteoarthritis clinical trials and nonclinical stage products. It also covers the Knee osteoarthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Knee Osteoarthritis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Knee Osteoarthritis clinical trials studies, Knee Osteoarthritis NDA approvals (if any), and product development activities comprising the technology, Knee osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Knee Osteoarthritis Pipeline Report

 

• DelveInsight’s Knee Osteoarthritis Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Knee Osteoarthritis treatment.

 

• The leading Knee Osteoarthritis Pipeline Companies includes Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, Biosplice Therapeutics, Jiangsu XinChen-Techfields Pharma Co., LTD., Teva Pharmaceutical Industries, Pfizer, Grünenthal GmbH, PMG Pharm Co., Ltd, Nordic Bioscience A/S, BUZZZ Pharmaceuticals Limited, Antibe Therapeutics, Saol Therapeutics Inc, LG Chem, and others.

 

• Promising Knee Osteoarthritis Pipeline Therapies includes JTA-004, MM-II, Elixcyte, GXCPC1, PTP-001, Canakinumab, LNA043, PSC-01, CNTX-4975-05, StroMel, Lorecivivint, V120083, Cingal, PPV-06, FX201, TLC599, X0002, MEDI7352, Ampion, Resiniferatoxin, TPX 100, AMZ001, EP-104IAR, Adalimumab, Fasinumab, XT-150, YYD302, LRX712, Celltex- AdMSCs, Tanezumab, Lopain, PK101,DFV 890, Canakinumab, AS-902330, G001, ATB-346, Teriparatide, SL-1002, QUC 398, LEVI 04, LG00034053, JOINTSTEM, and others.

 

• The Knee Osteoarthritis companies and academics are working to assess challenges and seek opportunities that could influence Knee osteoarthritis R&D. The Knee Osteoarthritis pipeline therapies under development are focused on novel approaches to treat/improve Knee osteoarthritis.

 

To explore more information on the latest breakthroughs in the Knee Osteoarthritis Pipeline treatment landscape of the report, click here @ Knee Osteoarthritis Pipeline Outlook

 

Knee Osteoarthritis Overview

 

Knee osteoarthritis is defined by degeneration of the knee’s articular cartilage—the flexible, slippery material that normally protects bones from joint friction and impact. The condition also involves changes to the bone underneath the cartilage and can affect nearby soft tissues. The defining feature of osteoarthritis is the breakdown and loss of articular cartilage. In the knee, articular cartilage covers the top of the tibia (shinbone), the bottom of the femur (thigh bone) and the back of the patella (kneecap). Articular cartilage protects the surfaces of these bones where they meet at the joint.

 

Latest Developmental Activities in the Knee Osteoarthritis Treatment Landscape

 

• In October 2022, Eupraxia Pharmaceuticals Inc. announced updates to its Phase II trial, which is evaluating EP-104IAR’s efficacy and safety for the treatment of osteoarthritis (“OA”) of the knee.Eupraxia announced that its ongoing Phase II study has successfully completed all DSMB reviews, with no drug-related Serious Adverse Events noted and a clean safety profile.

 

• In September 2022, KiOmed Pharma and Hansoh Pharmaceutical Group Company Limited announced a license agreement for the development and commercialization of KiOmedinevsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee osteoarthritis, in China’s mainland, Macau and Taiwan (the territory).Under the terms of the agreement, KiOmed will receive an upfront payment and will be eligible to receive development, regulatory and commercial milestones of up to € 66 million, as well as tiered royalties on future product sales.

 

• In September 2022, Pluri Inc. announced that a €7.5 million non-dilutive grant from the European Union’s Horizon Europe program had been awarded to PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis), an international collaboration led by Charité, Berlin Institute of Health Center for Regenerative Therapies. The goal of the PROTO project is to utilize Pluri’s PLX-PAD cells in Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis (OA).

 

• In September 2022, Immunis Inc. formally signed a clinical trial agreement with the California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase I/IIa clinical trials. The trials will assess the safety and tolerability of Immunis’ immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy related to knee osteoarthritis, an inflammatory disease that is a leading cause of disability in elderly adults.

 

• In June 2022, MiMedx Group, Inc. announced a collaboration agreement with Nordic Bioscience Clinical Development A/S (NBCD), a world-class Contract Research Organization (CRO) specializing in Osteoarthritis (OA) clinical trials.The Company plans to initiate its registrational Knee Osteoarthritis (KOA) clinical trial program later this year, using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and WOMAC Function as co-primary endpoints.

 

• In June 2022, Endo International plc announced that its subsidiary Endo Ventures Limited (EVL) had executed an agreement with Taiwan Liposome Company, Ltd. (TLC) to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in Phase III development for the treatment of osteoarthritis knee pain.

 

 

For further information, refer to the detailed Knee Osteoarthritis Unmet Needs, Knee Osteoarthritis Market Drivers, and Knee Osteoarthritis Market Barriers, click here for Knee Osteoarthritis Ongoing Clinical Trial Analysis

 

Knee Osteoarthritis Emerging Drugs Profile

 

• JTA-004: Bone Therapeutics

 

JTA-004 is Bone Therapeutics’ next generation of intra-articular injectable, which is currently in phase III development for the treatment of osteoarthritic pain in the knee. Consisting of a unique patented mix of plasma proteins, hyaluronic acid – a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain.

 

• MM-II: Moebius Medical

 

Moebius’s lead product, MM-II, is a novel non-opioid intra-articular injection that leverages the physical properties of proprietary multilamellar liposomes and an innovative mechanism-of-action to provide sustainable relief of symptomatic knee pain in osteoarthritic patients. The drug is currently in phase II stage of development.

 

Knee Osteoarthritis Pipeline Therapeutics Assessment

 

There are approx. 40+ key companies which are developing the therapies for Knee osteoarthritis. The companies which have their Knee osteoarthritis drug candidates in the most advanced stage, i.e. phase III include, Bone Therapeutics.

 

Request a sample and discover the recent advances in Knee Osteoarthritis Ongoing Clinical Trial Analysis and Medications, click here @ Knee Osteoarthritis Treatment Landscape

 

Scope of the Knee Osteoarthritis Pipeline Report

 

• Coverage- Global

 

• Knee Osteoarthritis Companies- includes Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, Biosplice Therapeutics, Jiangsu XinChen-Techfields Pharma Co., LTD., Teva Pharmaceutical Industries, Pfizer, Grünenthal GmbH, PMG Pharm Co., Ltd, Nordic Bioscience A/S, BUZZZ Pharmaceuticals Limited, Antibe Therapeutics, Saol Therapeutics Inc, LG Chem, and others.

 

• Knee Osteoarthritis Pipeline Therapies- JTA-004, MM-II, Elixcyte, GXCPC1, PTP-001, Canakinumab, LNA043, PSC-01, CNTX-4975-05, StroMel, Lorecivivint, V120083, Cingal, PPV-06, FX201, TLC599, X0002, MEDI7352, Ampion, Resiniferatoxin, TPX 100, AMZ001, EP-104IAR, Adalimumab, Fasinumab, XT-150, YYD302, LRX712, Celltex- AdMSCs, Tanezumab, Lopain, PK101,DFV 890, Canakinumab, AS-902330, G001, ATB-346, Teriparatide, SL-1002, QUC 398, LEVI 04, LG00034053, JOINTSTEM, and others.

 

• Knee Osteoarthritis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Knee Osteoarthritis Market Drivers and Knee Osteoarthritis Market Barriers, click here @ Knee Osteoarthritis Unmet Needs and Analyst Views

 

Table of Content 

1. Introduction
2. Executive Summary
3. Knee osteoarthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Knee osteoarthritis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. JTA-004: Bone Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MM-II: Moebius Medical
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PPV-06: Peptinov
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Knee osteoarthritis Key Companies
21. Knee osteoarthritis Key Products
22. Knee osteoarthritis- Unmet Needs
23. Knee osteoarthritis- Market Drivers and Barriers
24. Knee osteoarthritis- Future Perspectives and Conclusion
25. Knee osteoarthritis Analyst Views
26. Knee osteoarthritis Key Companies
27. Appendix

 

Got Queries? Find out the related information on Knee Osteoarthritis Mergers and acquisitions, Knee Osteoarthritis Licensing Activities @ Knee Osteoarthritis Emerging Drugs, and Recent Trends

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/